Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

Patent
Eleven Biotherapeutics | Date: 2014-03-13

Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.


Patent
Eleven Biotherapeutics | Date: 2014-08-15

Featured herein are non-naturally occuring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, strands, and loops from at least two parental cytokines domains.


Patent
Eleven Biotherapeutics | Date: 2012-11-18

The invention provides methods and materials for making and using variant serum albumin amino acid sequences which exhibit improved properties compared to wild type serum albumin sequences. The invention further provides methods and materials for making and using fusion proteins in which the variant serum albumin amino acid sequences are fused to a therapeutic or diagnostic agent, such as a therapeutic protein, or a functional fragment or variant thereof that maintains activity, and exhibits improved properties.


Patent
Eleven Biotherapeutics | Date: 2014-10-07

IL-6 antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.


Patent
Eleven Biotherapeutics | Date: 2014-05-02

The invention relates to methods of identifying albumin variants having improved pharmacokinetics, albumin variants having improved pharmacokinetics, and therapeutic uses of albumin variants having improved pharmacokinetics.


Patent
Eleven Biotherapeutics | Date: 2011-07-29

Featured herein are non-naturally occurring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1 RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, strands, and loops from at least two parental cytokines domains.


Patent
Eleven Biotherapeutics | Date: 2011-06-23

Disclosed herein are methods for administering an IL-1 or IL-17 antagonist for treating ocular surface disorders, e.g., a dry eye disorder. The antagonists can be administered topically using an opthalmic composition.


Patent
Eleven Biotherapeutics | Date: 2012-07-27

The present invention provides methods and compositions for the preparation and delivery of chimeric cytokine proteins, including cell cultures, methods of purification and purified compositions.


Patent
Eleven Biotherapeutics and Stanford University | Date: 2010-10-11

Binding proteins, including non-naturally occurring and recombinantly modified proteins that bind to an IL-17R and including proteins having a mutated IL-17 cytokine sequence, methods of making such molecules and methods of using such molecules as therapeutic, prophylactic and diagnostic agents are provided.


News Article | March 1, 2017
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen HurlPy, President and Chief Executive Officer, will present a company overview at two upcoming investor conferences. Details are as follows: A live webcast of both events will be available under “Events & Presentations” in the Investors & Media section of Eleven's website, www.elevenbio.com. An archived replay of the presentations will be available on the Company's website approximately one hour after the live events and will be available for 90 days following the presentations. Eleven Biotherapeutics, Inc. is a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based upon the Company's targeted protein therapeutics (TPTs) platform. The Company's TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. The Company believes its TPT approach offers significant advantages in treating cancer over existing antibody drug conjugate technologies. The Company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads that require tumor cell proliferation and face multi-drug resistance mechanisms. Additionally, the Company believes that its TPT's cancer cell-killing properties promote an anti-tumor immune response that will potentially combine well with immune oncology drugs such as checkpoint inhibitors. For more information please refer to the Company's website at www.elevenbio.com.

Loading Eleven Biotherapeutics collaborators
Loading Eleven Biotherapeutics collaborators